- Home
- SYNA vs PTGX Comparison
SYNA vs PTGX Comparison
Compare SYNA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNA
- PTGX
- Stock Information
- Founded
- SYNA 1986
- PTGX 2006
- Country
- SYNA United States
- PTGX United States
- Employees
- SYNA N/A
- PTGX N/A
- Industry
- SYNA Computer peripheral equipment
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SYNA Technology
- PTGX Health Care
- Exchange
- SYNA Nasdaq
- PTGX Nasdaq
- Market Cap
- SYNA 3.2B
- PTGX 2.8B
- IPO Year
- SYNA 2002
- PTGX 2016
- Fundamental
- Price
- SYNA $74.64
- PTGX $41.11
- Analyst Decision
- SYNA Strong Buy
- PTGX Strong Buy
- Analyst Count
- SYNA 11
- PTGX 7
- Target Price
- SYNA $99.60
- PTGX $53.57
- AVG Volume (30 Days)
- SYNA 495.6K
- PTGX 529.7K
- Earning Date
- SYNA 11-07-2024
- PTGX 11-07-2024
- Dividend Yield
- SYNA N/A
- PTGX N/A
- EPS Growth
- SYNA N/A
- PTGX N/A
- EPS
- SYNA 3.95
- PTGX 2.68
- Revenue
- SYNA $979,400,000.00
- PTGX $323,795,000.00
- Revenue This Year
- SYNA $13.30
- PTGX $396.93
- Revenue Next Year
- SYNA $15.55
- PTGX N/A
- P/E Ratio
- SYNA $18.89
- PTGX $15.32
- Revenue Growth
- SYNA N/A
- PTGX 125.73
- 52 Week Low
- SYNA $67.83
- PTGX $16.01
- 52 Week High
- SYNA $121.37
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- SYNA 51.19
- PTGX 31.67
- Support Level
- SYNA $71.80
- PTGX $45.23
- Resistance Level
- SYNA $81.49
- PTGX $48.86
- Average True Range (ATR)
- SYNA 3.22
- PTGX 2.16
- MACD
- SYNA 0.42
- PTGX -0.79
- Stochastic Oscillator
- SYNA 49.60
- PTGX 17.99
About SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.